Immunoregulatory Therapy for 2019-nCoV
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04268537|
Recruitment Status : Not yet recruiting
First Posted : February 13, 2020
Last Update Posted : February 13, 2020
|Condition or disease||Intervention/treatment||Phase|
|2019 nCoV, PD-1||Drug: PD-1 blocking antibody+standard treatment Drug: Thymosin+standard treatment Other: standard treatment||Phase 2|
Sepsis, including viral infections, are major causes of death worldwide. Studies show that in 2017, the number of sepsis patients worldwide reached as high as 48.9 million, of which eleven million patients died. Studies in China also showed that more than one million patients died of sepsis in 2015. Therefore, how to effectively reduce the mortality of patients with sepsis has become a focus of clinical and basic research.
Previous studies have suggested that sepsis are often secondary to excessive inflammatory response syndrome. However, treatment measures targeting excessive inflammatory response failed to effectively improve the prognosis of patients. The reason is that sepsis-related immune dysfunction can increase the risk of secondary infection and even affect the fatality rate.
The immune checkpoint pathway is the endogenous component of the immune system, which is responsible for checking the immune response and keeping it in a normal physiological state. Tumor cells can evade host recognition through this pathway. One of these immunocheckpoint pathways is the PD-1 and PD-L1 pathways. PD-1 is a receptor expressed on the surface of T cells and ACTS as a negative regulator of T cell function. Monoclonal antibody blocking the activity of PD-1 can successfully reduce tumor load and has been widely used in the clinical treatment of various tumors.
The immune imbalance in patients with sepsis has many similarities tumors. PD-1 and PD-L1 are key mediators in T cell depletion in sepsis patients. Animal models have shown that blocking PD-1 or PD-L1 can prevent T cell death, regulate cytokine production, reduce organ dysfunction and reduce death in sepsis. Previous study showed the clinical safety of anti-PD-1 antibody in sepsis patients through randomized, placebo-controlled trials.
Thymosin has also been proved to regulate cellular immunity in sepsis patients. Some studies have shown that thymosin can significantly reduce the mortality of sepsis patients. At present, phase III clinical research is in progress to further clarify the role of thymosin in patients with sepsis. The purpose of this study was to investigate the efficacy of PD-1 and thymosin in patients with severe pneumonia associated with lymphocytopenia in 2019 novel coronavirus infection.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients|
|Estimated Study Start Date :||February 10, 2020|
|Estimated Primary Completion Date :||April 30, 2020|
|Estimated Study Completion Date :||October 31, 2020|
Experimental: PD-1 group
Anti-PD-1 antibody, 200mg, IV, one time
Drug: PD-1 blocking antibody+standard treatment
After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Experimental: thymosin group
Thymosin, 1.6 mg sc qd, last for 5 days
Drug: Thymosin+standard treatment
Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Placebo Comparator: control group
Other: standard treatment
Standard treatment is according to the protocol of treatment of 2019-nCoV infection
- lung injury score [ Time Frame: 7 days ]proportion of lung injury score decreased 1 or more points
- absolute lymphocyte counts [ Time Frame: 7, 14 and 28 days ]lymphocyte counts at day 7, 14 and 28 after randimization
- serum level of CRP, PCT and IL-6 [ Time Frame: 3, 7 and 14 days ]serum level of CRP, PCT and IL-6 at day 3,7 and 14 after randimization
- SOFA score [ Time Frame: 7 days ]SOFA score at Day 7, with scores range from 0 to 24 and higher score means worse outcome
- all cause mortality rate [ Time Frame: 28 days ]died at day 28
- ventilation free days [ Time Frame: 28 days ]
- ICU free days [ Time Frame: up to 28 days ]